ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
Public ClinicalTrials.gov record NCT05216224. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ATI-450 vs Placebo in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2a study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of ATI-450 vs placebo in patients with moderate to severe Hidradenitis Suppurativa (HS).
Study identification
- NCT ID
- NCT05216224
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 95 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 29, 2021 (Actual)
- Primary completion
- Dec 23, 2022 (Actual)
- Completion
- Jan 24, 2023 (Actual)
- Last update posted
- Jan 7, 2026
2021 – 2023
United States locations
- U.S. sites
- 20
- U.S. states
- 13
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Aclaris Investigational Site | Birmingham | Alabama | 35244 | — |
| Aclaris Investigational Site | Fort Smith | Arkansas | 72916 | — |
| Aclaris Investigational Site | Encino | California | 91436 | — |
| Aclaris Investigational Site | San Francisco | California | 94115 | — |
| Aclaris Investigational Site | Thousand Oaks | California | 91436 | — |
| Aclaris Investigational Site | Boca Raton | Florida | 33486 | — |
| Aclaris Investigational Site | Hollywood | Florida | 33021 | — |
| Aclaris Investigational Site | Tampa | Florida | 33613 | — |
| Aclaris Investigational Site | Marietta | Georgia | 30060 | — |
| Aclaris Investigational Site | Sandy Springs | Georgia | 30328 | — |
| Aclaris Investigational Site | Metairie | Louisiana | 70006 | — |
| Aclaris Investigational Site | Fort Gratiot | Michigan | 48059 | — |
| Aclaris Investigational Site | Charlotte | North Carolina | 28277 | — |
| Aclaris Investigational Site | Athens | Ohio | 45701 | — |
| Aclaris Investigational Site | Mason | Ohio | 45040 | — |
| Aclaris Investigational Site | Hershey | Pennsylvania | 17033 | — |
| Aclaris Investigational Site | Anderson | South Carolina | 29621 | — |
| Aclaris Investigational Site | Nashville | Tennessee | 37215 | — |
| Aclaris Investigational Site | Houston | Texas | 77054 | — |
| Aclaris Investigational Site | Sugar Land | Texas | 77478 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05216224, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 7, 2026 · Synced Oct 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05216224 live on ClinicalTrials.gov.